Detalhes bibliográficos
| Autor(a) principal: |
Mendes, Paulo J. |
| Data de Publicação: |
2013 |
| Outros Autores: |
Viana, H.,
Marques, C. S.,
Burke, Anthony J. |
| Tipo de documento: |
Artigo de conferência
|
| Idioma: |
eng |
| Título da fonte: |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| Texto Completo: |
http://hdl.handle.net/10174/8856
|
Resumo: |
Nowadays neurodegenerative diseases such as Alzheimer’s disease and Parkinson disease represent a worldwide health threat. Rasagiline is one well-known medication for the treatment of Parkinson's disease, but more and cheaper alternatives are required.1 For this reason, our group is currently investigating a new catalytic asymmetric arylating2 cyclization route - borylation-arylation-amination (BorArAm) (Scheme 1) giving useful potential lead compounds based on the rasagiline core structure for treating these diseases. Our results will be discussed in this communication. |